GH Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of -55% compared to Guardant Health's net margin of -22.5%. Guardant Health's return on equity of -8518.58% beat Delcath Systems's return on equity of -117.89%.

Guardant Health has a consensus price target of $56.85, signalling upside risk potential of 24.02%. On the other hand Delcath Systems has an analysts' consensus of $22.50 which suggests that it could grow by 68.79%. Given that Delcath Systems has higher upside potential than Guardant Health, analysts believe Delcath Systems is more attractive than Guardant Health.

Guardant Health has a beta of 1.500, which suggesting that the stock is 49.959% more volatile than S&P 500. In comparison Delcath Systems has a beta of 0.820, suggesting its less volatile than the S&P 500 by 17.957%.

Guardant Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

Guardant Health quarterly revenues are $201.8M, which are larger than Delcath Systems quarterly revenues of $15.1M. Guardant Health's net income of -$111M is lower than Delcath Systems's net income of -$3.4M. Notably, Guardant Health's price-to-earnings ratio is -- while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health is 7.61x versus 10.54x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

Exact Sciences has a net margin of -55% compared to Guardant Health's net margin of -121.19%. Guardant Health's return on equity of -8518.58% beat Exact Sciences's return on equity of -34.11%.

Guardant Health has a consensus price target of $56.85, signalling upside risk potential of 24.02%. On the other hand Exact Sciences has an analysts' consensus of $69.43 which suggests that it could grow by 54.56%. Given that Exact Sciences has higher upside potential than Guardant Health, analysts believe Exact Sciences is more attractive than Guardant Health.

Guardant Health has a beta of 1.500, which suggesting that the stock is 49.959% more volatile than S&P 500. In comparison Exact Sciences has a beta of 1.248, suggesting its more volatile than the S&P 500 by 24.844%.

Guardant Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

Guardant Health quarterly revenues are $201.8M, which are smaller than Exact Sciences quarterly revenues of $713.4M. Guardant Health's net income of -$111M is higher than Exact Sciences's net income of -$864.6M. Notably, Guardant Health's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health is 7.61x versus 3.00x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Natera has a net margin of -55% compared to Guardant Health's net margin of -11.3%. Guardant Health's return on equity of -8518.58% beat Natera's return on equity of -21.3%.

Guardant Health has a consensus price target of $56.85, signalling upside risk potential of 24.02%. On the other hand Natera has an analysts' consensus of $187.94 which suggests that it could grow by 25.42%. Given that Natera has higher upside potential than Guardant Health, analysts believe Natera is more attractive than Guardant Health.

Guardant Health has a beta of 1.500, which suggesting that the stock is 49.959% more volatile than S&P 500. In comparison Natera has a beta of 1.804, suggesting its more volatile than the S&P 500 by 80.383%.

Guardant Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health pays -- of its earnings as a dividend. Natera pays out -- of its earnings as a dividend.

Guardant Health quarterly revenues are $201.8M, which are smaller than Natera quarterly revenues of $476.1M. Guardant Health's net income of -$111M is lower than Natera's net income of -$53.8M. Notably, Guardant Health's price-to-earnings ratio is -- while Natera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health is 7.61x versus 11.01x for Natera. Usually stocks with elevated PS ratios are considered overvalued.

Star Equity Holdings has a net margin of -55% compared to Guardant Health's net margin of -14.37%. Guardant Health's return on equity of -8518.58% beat Star Equity Holdings's return on equity of -17.45%.

Guardant Health has a consensus price target of $56.85, signalling upside risk potential of 24.02%. On the other hand Star Equity Holdings has an analysts' consensus of $10.00 which suggests that it could grow by 284.63%. Given that Star Equity Holdings has higher upside potential than Guardant Health, analysts believe Star Equity Holdings is more attractive than Guardant Health.

Guardant Health has a beta of 1.500, which suggesting that the stock is 49.959% more volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.075, suggesting its less volatile than the S&P 500 by 92.536%.

Guardant Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.

Guardant Health quarterly revenues are $201.8M, which are larger than Star Equity Holdings quarterly revenues of $17.1M. Guardant Health's net income of -$111M is lower than Star Equity Holdings's net income of -$2.5M. Notably, Guardant Health's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health is 7.61x versus 0.15x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.